In the title complex, bis-{μ-1-[(1H-benzimidazol-1-yl)meth-yl]-1H-1,2,4-triazole}disilver(I) dinitrate, [Ag(2)(C(10)H(9)N(5))(2)](NO(3))(2), the Ag(I) ion is nearly linearly coordinated [N-Ag-N angle is 155.72 (14)°] by two 1-[(1H-benzimidazole-1-yl)meth-yl]-1H-1,2,4-triazole (bmt) ligands. In addition, two bmt ligands link two Ag(I) ions, forming a dinuclear unit with an Ag⋯Ag distance of 5.0179 (15) Å. The whole complex is generated by an inversion centre. The dinuclear units and the NO(3) (-) counter-ions are connected by N-H⋯O hydrogen bonds and weak Ag⋯O inter-actions [2.831 (5), 2.887 (5) and 2.908 (5) Å], leading to a three-dimensional structure.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3238699 | PMC |
| http://dx.doi.org/10.1107/S1600536811048501 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of inhibitory KIR ligand mismatch and other variables on outcomes following myeloablative posttransplant cyclophosphamide-based T-cell-replete haploidentical bone marrow transplantation.
Front Immunol
December 2024
German Cancer Consortium (DKTK), Partner site Frankfurt/Mainz, a partnership between DKFZ and University Medical Center Frankfurt, Frankfurt, Germany.
Introduction: Posttransplant cyclophosphamide (PTCy) has revolutionized the landscape of human leukocyte antigen (HLA)-haploidentical hematopoietic cell transplantation (haplo-HCT), providing a pivotal therapeutic option for patients with hematological malignancies who lack an HLA-matched donor.
Methods: In this retrospective analysis involving 54 adult patients undergoing PTCy-based haplo-HCT, we evaluated the impact of inhibitory killer immunoglobulin-like receptor (KIR)/HLA mismatch, alongside patient, donor, and transplant factors, on clinical outcomes within a homogeneous cohort characterized by a myeloablative conditioning regimen and bone marrow graft.
Results: With a median follow-up of 73.
Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort.
United European Gastroenterol J
November 2024
Department of Medicine I, University Medical Center-Campus Lübeck, Lübeck, Germany.
Background: Combined Immuno-chemotherapy consisting of gemcitabine, cisplatin and the programmed death-ligand one inhibitor durvalumab (GCD) is the new standard of care for patients with biliary tract cancers (BTC) based on positive results of the TOPAZ-1 study.
Objective: We here evaluated the efficacy and safety of GCD for BTC in a German multicenter real-world patient cohort.
Methods: Patients with BTC treated with GCD from 9 German centers were included.
Donor genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight.
Front Immunol
April 2024
Institute for Experimental Cellular Therapy, University Hospital, Essen, Germany.
Optimizing natural killer (NK) cell alloreactivity could further improve outcome after allogeneic hematopoietic cell transplantation (alloHCT). The donor's Killer-cell Immunoglobulin-like Receptor (KIR) genotype may provide important information in this regard. In the past decade, different models have been proposed aiming at maximizing NK cell activation by activating KIR-ligand interactions or minimizing inhibitory KIR-ligand interactions.
View Article and Find Full Text PDFACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis.
Cancers (Basel)
December 2023
Hematology Unit with BMT, A.O.U. Policlinico "G.Rodolico-San Marco", 95123 Catania, Italy.
Article Synopsis
- Activin receptor type I (ACVR1) is a key receptor in the BMP signaling pathway that regulates hepcidin, which controls iron levels and can lead to anemia when elevated.
- Anemia is a major issue for myelofibrosis (MF) patients, negatively affecting their prognosis and associated with bone marrow issues and systemic symptoms.
- Recent advancements include the approval of momelotinib for treating MF-related anemia and ongoing clinical trials for other ACVR1 inhibitors, offering hope for better outcomes in anemic MF patients.
Genetic and pharmaceutical targeting of HIF1α allows combo-immunotherapy to boost graft vs. leukemia without exacerbation graft vs. host disease.
Cell Rep Med
November 2023
Division of Immunotherapy, Institute of Human Virology, Department of Surgery and Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Electronic address:
Despite potential impact on the graft vs. leukemia (GVL) effect, immunotherapy targeting CTLA-4 and/or PD-1 has not been successfully combined with bone marrow transplant (BMT) because it exacerbates graft vs. host disease (GVHD).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!